The disclosed and described technology relates generally to the thermal treatment of visceral fat. More specifically, embodiments of the present invention relate to systems, devices and methods for cryolipolysis of visceral fat.
Visceral fat is technically excess intra-abdominal adipose tissue accumulation. In other words, it is known as a “deep” fat that is stored farther beneath the skin than subcutaneous belly fat. Visceral fat is a gel-like fat that wraps around major organs including the liver, pancreas and kidneys. Visceral fat is especially dangerous because the visceral fat cells change the way the body operates.
Carrying excess visceral fat is linked with an increased risk of: coronary heart disease, cancer, stroke, dementia, diabetes, depression, arthritis, obesity, sexual dysfunction and various sleep disorders. (See Neeb Z, Edwards J, Alloosh M, Long X, Mokelke E, Sturek M, “Metabolic Syndrome and Coronary Artery Disease in Ossabaw Compared With Yucatan Swine,” Comparative Medicine (2010) 60:300-15: Després J, Moorjani S, Lupien P, Tremblay A, Nadeau A, Bouchard C, “Regional Distribution of Body Fat, Plasma Lipoproteins, and Cardiovascular Disease,” Arteriosclerosis (1990) 10:497-511; Lemieux I, Pascot A, Prud'homme D, Alméras N, Bogaty P, Nadeau A, Bergeron J, Després J, “Elevated C-Reactive Protein: Another Component of the Atherothrombotic Profile of Abdominal Obesity,” Arteriosclerosis, Thrombosis, and Vascular Biology. (2001) 21:961-67; Pascot A, Lemieux I, Prud'homme D, Tremblay A, Nadeau A, Couillard C, Bergeron J, Lamarche B, Després J, “Reduced HDL Particle Size as an Additional Feature of the Atherogenic Dyslipidemia of Abdominal Obesity,” Journal of Lipid Research (2001) 42:2007-14; Pouliot M. Després J. Nadeau A. Moorjani S, Prud'homme D, Lupien P, Tremblay A, Bouchard C, “Visceral Obesity in Men. Associations With Glucose Tolerance, Plasma Insulin, and Lipoprotein Levels,” Diabetes (1992) 41:826-34; Tchernof A, Lamarche B, Prud'homme D, Nadeau A, Moorjani S, Labrie F, Lupien J, Després J, “The Dense LDL Phenotype. Association With Plasma Lipoprotein Levels, Visceral Obesity, and Hyperinsulinemia in Men,” Diabetes Care (1996) 19:629-37; Ross R, Aru J, Freeman J, Hudson R, Janssen I, “Abdominal Adiposity and Insulin Resistance in Obese Men,” American Journal of Physiology, Endocrinology and Metabolism, (2002) 282:E657-E663; Ross R. Freeman J. Hudson R, Janssen I, “Abdominal Obesity, Muscle Composition. and Insulin Resistance in Premenopausal Women,” The Journal of Clinical Endocrinology and Metabolism, (2002) 87:5044-51; Mertens I, Van der Planken M, Corthouts B, Van Gaal L, “Is Visceral Adipose Tissue a Determinant of Von Willebrand Factor in Overweight and Obese Premenopausal Women?” Metabolism: Clinical and Experimental, (2006) 55:650-55; Brunzell J, Hokanson J, “Dyslipidemia of Central Obesity and Insulin Resistance,” Diabetes Care, (1999) 22 Suppl 3:C10-C13; Nieves D, Cnop M, Retzlaff B, Walden C, Brunzell J, Knopp R, Kahn S, “The Atherogenic Lipoprotein Profile Associated With Obesity and Insulin Resistance is Largely Attributable to Intra-Abdominal Fat,” Diabetes, (2003) 52:172-79; Boyko E, Leonetti D, Bergstrom R, Newell-Morris L, Fujimoto W, “Visceral Adiposity, Fasting Plasma Insulin, and Lipid and Lipoprotein Levels in Japanese Americans,” International Journal of Obesity and Related Metabolic Disorders. (1996) 20: 801-08.)
Visceral fat is considered toxic and is doubly troubling because it's capable of provoking inflammatory pathways and also signals and activates molecules that can interfere with the body's normal hormonal functions. In fact, visceral fat acts like its very own organ because it is capable of having a very large impact on body function as it continuously produces hormones and inflammatory substances.
Storing excess fat around the organs increases the production of pro-inflammatory chemicals/substances called cytokines, which leads to inflammation while at the same time, interferes with hormones that regulate appetite, weight, mood and brain function.
Accordingly, embodiments of the present invention are directed to methods, systems and devices that use non-ablative cold temperatures to treat visceral fat.
An aspect of the present invention is directed towards a system for providing alternating cooling and warming cycles. In one embodiment the system includes a controller, a vessel for holding a working fluid, a pressure generator, a cooler, a cooler heat exchanger, a heater, a heater heat exchanger, a check valve, and a treatment instrument. In some embodiments, the treatment instrument includes a distal treatment section, a proximal end, a connecting portion adjacent to the proximal end, and a handle portion disposed between the proximal and distal end. The working fluid can be alcohol ethanol, octafluoropropane, diethyl ether or propylene glycol.
Another aspect of the present invention is directed to a treatment instrument for treating visceral fat. The treatment instrument includes a distal end, a proximal end, a connecting portion adjacent the proximal end, a needle element adjacent the distal end, a distal treatment section adjacent the distal end, and a handle portion disposed between the proximal and distal end. In some embodiments, the treatment device also includes a heating element.
Another aspect of the present invention is directed to a treatment instrument for treating visceral fat, where the treatment instrument comprises a distal end, a proximal end, a connecting portion adjacent the proximal end, a distal treatment section adjacent the distal end and a handle portion disposed between the proximal and distal end. In some embodiments, the distal treatment section comprises a plurality of concentric loops.
A further aspect of the present invention is a method of treating visceral fat. The method comprises the steps of identifying visceral fat to be treated, inserting a laparoscopic device into the visceral fat to be treated, inserting a treatment instrument into the laparoscopic device such that a distal treatment section of the treatment device is delivered into the visceral fat, cooling the distal treatment section and the visceral fat adjacent to the distal treatment section to a cooling temperature no colder than approximately −20° C., and warming the distal treatment section and the visceral fat adjacent to the distal treatment section to a temperature greater than the cooling temperature.
In another embodiment, the invention is directed to a method of treating visceral fat. The method comprises the steps of identifying visceral fat to be treated, inserting a laparoscopic device into a first area of the visceral fat to be treated, inserting a treatment instrument into the laparoscopic device such that a distal treatment section of the treatment device is delivered into the first area of the visceral fat, cooling the distal treatment section and the first area of the visceral fat adjacent to the distal treatment section to a cooling temperature no colder than approximately −20° C., warming the distal treatment section and the first area of the visceral fat adjacent to the distal treatment section to a temperature greater than the cooling temperature, removing the treatment instrument and the distal treatment section of the treatment instrument from the first area of visceral fat, removing the laparoscopic device from the first area of visceral fat, inserting the laparoscopic device into a second area of the visceral fat to be treated, inserting the treatment instrument into the laparoscopic device such that the distal treatment section of the treatment device is delivered into the second area of the visceral fat, cooling the distal treatment section and the second area of visceral fat adjacent to the distal treatment section to a cooling temperature no colder than approximately −20° C. and warming the distal treatment section and the second area of the visceral fat adjacent to the distal treatment section to a temperature greater than the cooling temperature.
Another aspect of the present invention is directed to a method of treating visceral fat where the method comprises the steps of identifying visceral fat to be treated, inserting a treatment instrument into the visceral fat such that a distal treatment section of the treatment device is delivered into a first area of the visceral fat, cooling the distal treatment section and the first area of the visceral fat adjacent to the distal treatment section to a cooling temperature no colder than approximately −20° C., warming the distal treatment section and the first area of the visceral fat adjacent to the distal treatment section to a temperature greater than the cooling temperature, removing the treatment instrument and the distal treatment section of the treatment instrument from the first area of visceral fat, inserting the treatment instrument and the distal treatment section of the treatment instrument into a second area of the visceral fat, cooling the distal treatment section and the second area of visceral fat adjacent to the distal treatment section to a cooling temperature no colder than approximately −20° C., and warming the distal treatment section and the second area of the visceral fat adjacent to the distal treatment section to a temperature greater than the cooling temperature.
In another embodiment, the invention is directed to a method of treating visceral fat. The method comprises the steps of identifying visceral fat to be treated, inserting a treatment instrument into the visceral fat such that a distal treatment section of the treatment device is delivered into a first area of the visceral fat, cooling the distal treatment section and the first area of the visceral fat adjacent to the distal treatment section, warming the distal treatment section and the first area of the visceral fat adjacent to the distal treatment section to a temperature greater than the cooling temperature, removing the treatment instrument and the distal treatment section of the treatment instrument from the first area of visceral fat, inserting the treatment instrument and the distal treatment section of the treatment instrument into a second area of the visceral fat, cooling the distal treatment section and the second area of visceral fat adjacent to the distal treatment section, and warming the distal treatment section and the second area of the visceral fat adjacent to the distal treatment section to a temperature greater than the cooling temperature.
The description, objects and advantages of embodiments of the present invention will become apparent from the detailed description to follow, together with the accompanying drawings.
The above-mentioned aspects, as well as other features, aspects, and advantages of the present technology will now be described in connection with various embodiments, with reference to the accompanying drawings. The illustrated embodiments, however, are merely examples and are not intended to be limiting. Throughout the drawings, similar symbols typically identify similar components, unless context dictates otherwise. Note that the relative dimensions of the following figures may not be drawn to scale.
The disclosed and described technology relates to cryotherapy systems, devices and methods to treat various joint conditions including, and not limited to, arthritis.
The system employs an open thermodynamic cycle and uses a cryogen that is a high-density fluid with a freezing temperature below the treatment temperature. The fluid should not be hazardous (such as toxic, explosive, etc.) and must have a high density in order for it to be an efficient thermal agent. The fluid should also have a low viscosity such that it can flow through small channels and small diameter lumens within the treatment device without a significant pressure gradient and/or viscous heating. Sample high density fluids for use in the present system are included in Table 1.
Depicted in
Initially, the working fluid is maintained at ambient temperature (TA) and an elevated pressure (PIN). Under these conditions, the fluid should be well within its high-density phase. Some examples of a fluid's the high-density phase include the liquid phase and/or supercritical phase, which is where the fluid has the properties of both a liquid and a gas and which typically occurs above the liquid's critical point, i.e., above the liquid's critical temperature and critical pressure.
An embodiment of the cryotherapy system 10 is depicted in
For example, the pressure generator can be a mechanical piston system 18 that includes a piston head 20, a connecting rod/means 22 and at least one compression ring/gasket 24. The piston head 20 and connecting rod 22 can be driven by, for example, an electrical (stepper) motor. The pressures necessary to run the system can also be generated and maintained with the use of a closed volume system that contains the working fluid. As depicted in
Because the system has a dual function of freezing and thawing, a dual fluid flow is included. This is achieved with the use of a three-way valve 36 as depicted in
As can be seen in
Also included with the system 10 is a treatment instrument 48 (for example, a needle device) for insertion into skin. The treatment instrument 48 connects to the system through a three-port hermetic connector that connects the cold fluid supply line, warm fluid supply line, and a return fluid line from the system 10 to the treatment instrument 48. In some embodiments, multiple cold fluid supply lines and/or multiple warm fluid supply lines and/or multiple return fluid lines may be used.
Depicted in
As shown in
In some embodiments, the needle 50 length can range from approximately 1.0 mm to approximately 10.0 mm and extends form a handle portion 70 that, as depicted in
In some embodiments, the disk-like section 72 may include a heating element such as, for example, an electrical heater, that is used to prevent freezing of the upper most layer of skin (epidermis) by maintaining the temperature at a safe level, for example, approximately 30° C. to 42° C. The disk-like section 72 may also include a thermal sensor to monitor the temperature of the epidermis temperature in order to control the temperature of the heating element.
Following is a thermodynamic analysis for a needle 50 as depicted in
For the dimensions, assume a standard botox needle, which is 27 gauge. Such a needle can be constructed as follows:
Needle shaft (stainless steel): DN=0.41 mm; DO=0.25 mm
Inner tubing (polyimide): d1=0.13 mm; dø=0.10 mm
Annulus space will have its hydraulic diameter (dH) as follows:
d
H
=D−d
1=0.12 mm OR dH≅dø
Because the preferred working fluid is octafluoropropane, assume:
Assume laminar flow, for ΔP=PIN−POUT=100 psi (7×106 Pa)
The corresponding Reynold's Number:
Accordingly, the flow is very laminar.
Cooling power=power required to warm up the needle to 0° C.:
This amount of power is more than adequate to treat visceral fat as discussed herein.
In some embodiments, the system may include multiple treatment instruments, which may be operated independently of one another or which may be operated synchronously. Accordingly, in these embodiments, the system will include multiple connection ports/supply hoses.
As depicted in
As depicted in
In order to regulate the temperature for the freezing and thawing cycles, either of the following methods can be used. The freezing temperature (TFR) can be maintained by setting the cooler 44 temperature to some constant value, −25° C., for example, and regulating the fluid flow by changing pressure PIN of the working fluid flowing from the container 14 to the cooler 44. Similarly, the thawing temperature (TTH) can be maintained by setting the heater 46 temperature to some constant value, 38° C., for example, and regulating the fluid flow by changing pressure PIN of the working fluid flowing from the container 14 to the heater 46. Alternatively, the freezing temperature (TFR) can be maintained by setting the pressure PIN of the working fluid flowing from the container 14 to the cooler 44 to a constant pressure and changing the temperature of the cooler 44. Similarly, the thawing temperature (TTH) can be maintained by setting the pressure PIN of the working fluid flowing from the container 14 to the heater 46 to a constant pressure and changing the temperature of the heater 46. Either of the above methods may be used or a combination of the above methods may be used to regulate TFR and TTH.
The system 10 may also include a plurality of sensors such as pressure gauges 78 and thermistors that are used to monitor operation of the system 10 and to control the operating parameters for treatment procedures. Information obtained from these sensors can be displayed on the display 76 so that a user has real-time operating data for the system.
In some embodiments, the system 10 includes a flow meter in the working fluid cooling/freezing flow path 38 in order to measure fluid flow through the system and hence the system's cooling power.
Operation of the system 10 will now be described. The working fluid 12 is first added to container 14, where it is then pressurized by the pressure generator 16 to a predetermined pressure (PIN). Next, for a freeze cycle, the three-way valve 36 is actuated to open the flow path 38 to the cooler 44. The working fluid 12 is then delivered to the heat exchanger 42 for the cooler 44 where the working fluid 12 is cooled to a pre-set treatment freeze temperature (TFR). Once the working fluid 12 is cooled to TFR, the working fluid 12 is delivered the thermally insulated hose 58 to the treatment instrument 48, which is inserted into the target tissue to be cooled/frozen. Because the needle 50 of the treatment device 48 is in thermal contact with the target tissue, heat is removed from the target tissue by the flowing, cooled working fluid, thereby cooling/freezing the target tissue. Within the treatment device 48, the working fluid 12 flows into freeze channel/lumen 62, into the delivery channel/lumen 65, into to the flow chamber 53, then exits the flow chamber 53 by flowing into the return channels/lumens 66 and then exits the treatment device 48 through the return channels/lumens 66. Upon exiting the treatment device 48 through the return channels/lumens 66 and return lumen in the thermally insulated hose 58, the return flow of working fluid, which is now at a higher temperature (TOUT) and lower pressure (POUT) than it was before flowing through the treatment instrument 48, is delivered back to the console, which houses many of the system's components, and discharged to the atmosphere via a check valve 80 that is pre-set to a certain release pressure (PC). Using a check valve with a pre-set release pressure is required in order to maintain the working fluid in its high-density state throughout the freeze cycle. The pre-set release pressure (PC) of the check valve 80 is determined by the choice of working fluid that is used in the system 10. That is, different pressures are required to be maintained for different working fluids in order to maintain the working fluids in their high-density state. It is important to note that from the time the working fluid 12 is pressurized and leaves the container 14 until the time it is discharged to the atmosphere through the check valve 80, the working fluid 12 always remains in its high density state as can be seen in
The thaw cycle is similar to the freeze cycle except that the flow path of the working fluid 12 in the system 10 is different. For the thaw cycle, the three-way valve 36 is actuated to open the flow path 38 to the heater 46. The working fluid 12 is then delivered to the heat exchanger 42 for the heater 46 where the working fluid 12 is heated to a pre-set treatment thaw temperature (TTH). Once the working fluid 12 is heated to TTH, the working fluid 12 is delivered the thermally insulated hose 58 to the treatment instrument 48, which is inserted into the target tissue to be heated/thawed. Operation of the system 10 for all other aspects is similar to that of the freeze cycle. Again, as shown in
In another embodiment, the system can be a closed loop system. As used herein, “closed loop” means that instead of venting working fluid through a check valve to the atmosphere after it flows through the treatment instrument for either freezing or thawing, the working fluid is instead returned to the holding container for re-use by the system. This can be achieved by means of an external pump.
It is important to note that unlike prior systems (argon-based systems, for example), the cooling/freezing and warming/thawing effect in the present system does not occur at the treatment device. Instead, cooling and heating of the working fluid 12 are achieved using a dedicated cooler or heater prior to the working fluid entering the treatment device.
Procedures and methods to treat visceral fat using the disclosed and described systems and treatment devices will now be described. Embodiments of the present invention expose visceral fat to non-ablative cooling temperatures warmer than approximately −20° C. in order to induce fat cell apoptosis. The temperatures used induce fat cell apoptosis but do not have any deleterious effects on surrounding tissue and organs.
In some embodiments, the treatment device is inserted into the body and into the visceral fat using laparoscopic devices and methods. As is known by those of skill in the art, an incision can be made in the skin and the laparoscopic instrument, which can include a camera, is inserted through the skin and navigated to the visceral fat to be treated. As will be understood by those of skill in the art, other delivery devices may be used in place of lapascopic instruments to deliver the treatment device to the visceral fat.
Once the laparoscopic instrument is in place at the treatment site, the treatment device, which as depicted in
The length “L” of the distal treatment section 505 can vary from patient to patient and can be based on the target tissue being treated. Probes 500 can be manufactured to have different length distal treatment sections 505 or the length of the distal treatment section can be controlled by controlling the length of the distal treatment section that is exposed from the distal end of the laparoscope or other device used to deliver the probe 500 to the target tissue.
Treating visceral fat requires the distal treatment section 505 of the probe 500 to be maneuvered to different locations within the treatment are, which contains the visceral fat. Thus, in some embodiments, the probe 500 includes a warming function, which can be achieved in accordance with the embodiments disclosed and described herein. During treatments, after cooling the distal treatment section 505, the distal treatment section 505 can be warmed up to “unstick” the distal treatment section 505 from the location within visceral fat being treated. The probe 500 and hence the distal treatment section 505 can then be moved to another location within the visceral fat. This allows the procedure to be sped up as the distal treatment section 505 can be actively warmed to release it from tissue instead of waiting for the body tissue to naturally warm-up the distal treatment section 505, which can take time. In some embodiments, the treatment can include alternating cooling and warming cycles within the same location in the visceral fat.
In another embodiment, the treatment method includes identifying visceral fat to be treated. Once identified, a laparoscopic device or other delivery device is inserted into a first area of the visceral fat to be treated. After the delivery device is inserted at the desired location, the treatment instrument 500 is inserted into the delivery device such that the distal treatment section 505 of the treatment device 500 is delivered into the first area of the visceral fat. When in place, the distal treatment section 505 and the first area of the visceral fat adjacent to the distal treatment section 505 are cooled by circulating a working fluid through the distal treatment section 505 to a cooling temperature no colder than approximately −20° C. After a desired cooling time/period, which, in some embodiments can be approximately 10 minutes, the distal treatment section 505 and the first area of the visceral fat adjacent to the distal treatment section 505 are warmed to a temperature greater than the cooling temperature. In some embodiments, additional cooling and warming cycles are performed at the first area of the visceral fat. When the desired number of cooling and warming cycles are performed, the treatment instrument 500 and the distal treatment section 505 of the treatment instrument 500 are removed from the first area of visceral fat. In some embodiments, the treatment includes inserting the treatment instrument 500 and the distal treatment section 505 into a second area of the visceral fat and cooling the distal treatment section 505 and the second area of visceral fat adjacent to the distal treatment section 505 to a cooling temperature no colder than approximately −20° C. After the desired cooling time/period, the distal treatment section 505 and the second area of the visceral fat adjacent to the distal treatment section 505 are warmed to a temperature greater than the cooling temperature. In some embodiments, additional cooling and warming cycles are performed at the second area of the visceral fat. When the desired number of cooling and warming cycles are performed, the treatment instrument 500 and the distal treatment section 505 of the treatment instrument 500 are removed from the second area of visceral fat. In some embodiments, 3 and/or 4 and/or 5 and/or 6 and/or any additional number of areas of the visceral fat are cooled and warmed as disclosed and described herein. In some embodiments, instead of actively warming the areas of the visceral fat after the cooling cycle, the areas of the visceral fat are allowed to naturally warm up as a result of body temperature and not through active warming from the distal treatment section 505.
Another embodiment of the invention is depicted in
The distal treatment section 600 of this embodiment can be deployed through a guiding sheath laparoscopically. In this embodiment, the dimensions of the spiral or plurality of concentric loops configuration 605 is approximately 10.5 cm in diameter and forms four (4) loops 610. As will be understood by those of skill in the art, the loop configuration 605 can be designed to have different diameters with a different number of loops 610 depending on the size of fat tissue to be treated. The distance between the individual loops 610 was constant at 0.5 cm with a penetration depth into the tissue (P) at 2, 4 and 6 mm. Simplified anatomy was used for the location of the visceral fat and the cooling probe was analyzed to −15° C. while pressing the distal treatment section into the visceral fat tissue (see
Experimental Results
To show that the embodiments of the present invention can cool/freeze visceral fat and promote fat cell loss, a prototype was built with a distal treatment section having one loop 650 (see
Visceral fat tissue was fixed (4% paraformaldehyde) and cryo-processed for hematoxylin-eosin (H&E) staining (see
Additionally, the inventors measured the effect of cooling/freezing on apoptosis in visceral fat using the TUNNEL assay (see
As depicted in
Because cooling fat to temperatures of approximately 10° C. of colder induces fat cell apoptosis, treating visceral fat in accordance with the disclosed and described embodiments, can significantly reduce the mass of the visceral fat tissue thereby reducing and even eliminating the adverse effects caused by visceral fat as discussed herein.
The foregoing disclosure provides for embodiments of systems, devices and methods for treating joint conditions such as, for example, arthritis, etc. While several components, techniques and aspects have been described with a certain degree of particularity, it is manifest that many changes can be made in the specific designs, constructions and methodology herein above described without departing from the spirit and scope of this disclosure.
It is to be understood that the embodiments of the invention described herein are not limited to particular variations set forth herein as various changes or modifications may be made to the embodiments of the invention described and equivalents may be substituted without departing from the spirit and scope of the embodiments of the invention. As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features that may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the embodiments of the present invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process act(s) or step(s) to the objective(s), spirit or scope of the embodiments of the present invention. All such modifications are intended to be within the scope of the claims made herein.
Moreover, while methods may be depicted in the drawings or described in the specification in a particular order, such methods need not be performed in the particular order shown or in sequential order, and that all methods need not be performed, to achieve desirable results. Other methods that are not depicted or described can be incorporated in the example methods and processes. For example, one or more additional methods can be performed before, after, simultaneously, or between any of the described methods. Further, the methods may be rearranged or reordered in other implementations. Also, the separation of various system components in the implementations described above should not be understood as requiring such separation in all implementations, and it should be understood that the described components and systems can generally be integrated together in a single product or packaged into multiple products. Additionally, other implementations are within the scope of this disclosure.
Conditional language, such as “can,” “could,” “might,” or “may,” unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include or do not include, certain features, elements, and/or steps. Thus, such conditional language is not generally intended to imply that features, elements, and/or steps are in any way required for one or more embodiments.
Conjunctive language such as the phrase “at least one of X, Y, and Z,” unless specifically stated otherwise, is otherwise understood with the context as used in general to convey that an item, term, etc. may be either X, Y, or Z. Thus, such conjunctive language is not generally intended to imply that certain embodiments require the presence of at least one of X, at least one of Y, and at least one of Z.
Reference to a singular item, includes the possibility that there are plural of the same items present. More specifically, as used herein and in the appended claims, the singular forms “a,” “an,” “said” and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.
It will be understood that when an element is referred to as being “connected” or “coupled” to another element, it can be directly connected or coupled to the other element or intervening elements may be present. In contrast, if an element is referred to as being “directly connected” or “directly coupled” to another element, there are no intervening elements present.
It will be understood that, although the terms first, second, etc. may be used herein to describe various elements, these elements should not be limited by these terms. These terms are only used to distinguish one element from another. Thus, a first element could be termed a second element without departing from the teachings of the present invention.
Language of degree used herein, such as the terms “approximately,” “about,” “generally,” and “substantially” as used herein represent a value, amount, or characteristic close to the stated value, amount, or characteristic that still performs a desired function or achieves a desired result. For example, the terms “approximately”, “about”, “generally,” and “substantially” may refer to an amount that is within less than or equal to 10% of, within less than or equal to 5% of, within less than or equal to 1% of, within less than or equal to 0.1% of, and within less than or equal to 0.01% of the stated amount. If the stated amount is 0 (e.g., none, having no), the above recited ranges can be specific ranges, and not within a particular % of the value. Additionally, numeric ranges are inclusive of the numbers defining the range, and any individual value provided herein can serve as an endpoint for a range that includes other individual values provided herein. For example, a set of values such as 1, 2, 3, 8, 9, and 10 is also a disclosure of a range of numbers from 1-10, from 1-8, from 3-9, and so forth.
Some embodiments have been described in connection with the accompanying drawings. The figures are drawn to scale, but such scale should not be limiting, since dimensions and proportions other than what are shown are contemplated and are within the scope of the disclosed inventions. Distances, angles, etc. are merely illustrative and do not necessarily bear an exact relationship to actual dimensions and layout of the devices illustrated. Components can be added, removed, and/or rearranged. Further, the disclosure herein of any particular feature, aspect, method, property, characteristic, quality, attribute, element, or the like in connection with various embodiments can be used in all other embodiments set forth herein. Additionally, it will be recognized that any methods described herein may be practiced using any device suitable for performing the recited steps.
While a number of embodiments and variations thereof have been described in detail, other modifications and methods of using the same will be apparent to those of skill in the art. Accordingly, it should be understood that various applications, modifications, materials, and substitutions can be made of equivalents without departing from the unique and inventive disclosure herein or the scope of the claims.
This application claims the benefit of U.S. Provisional Application No. 62/732,831, filed Sep. 18, 2018, the entire contents of which are incorporated herein by reference in their entirety for all purposes.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2019/051746 | 9/18/2019 | WO | 00 |
Number | Date | Country | |
---|---|---|---|
62732831 | Sep 2018 | US |